Indeed, a recent phase 3 trial using nintedanib (an oral triple angiokinase inhibitor of VEGF receptor, PDGFR, and fibroblast growth factor receptor), in addition to platinum based chemotherapy showed improved PFS for ovarian cancer (17.2 months vs 16.6 months; p = 0.024) [19]. This evidence concerns the gene PDGFRB and ovarian carcinoma.